1,5-Diaryl-2-ethyl pyrrole derivatives as antimycobacterial agents: Design, synthesis, and microbiological evaluation

European Journal of Medicinal Chemistry

Volumn 44, Issue 11, 2009, Pages 4734-4738

  Biava, Mariangela ^a   Porretta, Giulio C ^a   Poce, Giovanna ^a   De Logu, Alessandro ^b   Meleddu, Rita ^b   De Rossi, Edda ^c   Manetti, Fabrizio ^d   Botta, Maurizio ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Dipartimento di Scienze e Tecnologie Biomediche   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

1,5 Diarylpyrroles; Antitubercular agents; BM 212; Mycobacterium tuberculosis; Pharmacophoric model

Indexed keywords

1 (4 FLUOROPHENYL) 2 ETHYL 3 (THIOMORPHOLIN 4 YL)METHYL 5 (4 METHYL PHENYL) 1H PYRROLE; 1,5 BIS(4 CHLOROPHENYL) 2 METHYL 3 (4 METHYL 1 PIPERAZINYLMETHYL)PYRROLE; 1,5 DIARYL 2 ETHYL PYRROLE DERIVATIVE; ANTIMYCOBACTERIAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTITUBERCULAR AGENTS; CERCOPITHECUS AETHIOPS; MODELS, MOLECULAR; MYCOBACTERIUM TUBERCULOSIS; PYRROLES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS; VERO CELLS;

EID: 70349765643     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.06.005     Document Type: Article

References (32)

1. Yew W.W., and Leung C.C. Am. J. Respir. Crit. Care Med. 177 (2008) 479-485
2. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2008 (2008), World Health Organization (WHO/HTM/TB/2008.393)
3. Breen R.A., Swaden L., Ballinger J., and Lipman M.C. Drugs 66 (2006) 2299-2308
4. Phillips K.D. J. Assoc. Nurses Aids Care 18 (2007) 75-78
5. Idemyor V. J. Natl. Med. Assoc. 99 (2007) 1414-1419
6. Pepper D.J., Meintjes G.A., McIlleron H., and Wilkinson R.J. Drug Discov. Today 12 (2007) 980-989
7. Espinal M.A. Tuberculosis 83 (2003) 44-51
8. Ormerod L.P. Br. Med. Bull. 73-74 (2005) 17-24
9. Caminero J.A. Int. J. Tuberc. Lung Dis. 10 (2006) 829-837
10. Biava M., Porretta G.C., Deidda D., and Pompei R. Curr. Drug Targets Infect. Disord. 6 (2006) 159-172
11. Yew W.W., and Leung C.C. Respirology 13 (2008) 21-46
12. Revised definition of extensively drug-resistant tuberculosis. MMWR Morb. Mortal. Wkly. Rep. 55 (2006) 1176
13. Dorman S.E., and Chaisson R.E. Nat. Med. 13 (2007) 295-298
14. Goldman R.C., Plumley K.V., and Laughon B.E. Infect. Disord. Drug Targets 7 (2007) 73-91
15. Tomioka H. Curr. Pharm. Des. 12 (2006) 4047-4070
16. Ziganshina L.E., and Squire S.B. Cochrane Database Syst. Rev. 1 (2008) CD004795
17. Ballell L., Field R.A., Duncan K., and Young R.J. Antimicrob. Agents Chemother. 49 (2005) 2153-2163
18. Spigelman M., and Gillespie S. Lancet 367 (2006) 945-947
19. Janin Y.L. Bioorg. Med. Chem. 15 (2007) 2479-2513
20. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 8 (2008) 15
21. Sacchettini J.C., Rubin E.J., and Freundlich J.S. Nat. Rev. Microbiol. 6 (2008) 41-52
22. Biava M., Porretta G.C., Poce G., De Logu A., Saddi M., Meleddu R., Manetti F., De Rossi E., and Botta M. J. Med. Chem. 51 (2008) 3644-3648
23. Biava M., Porretta G.C., Poce G., Supino S., Deidda D., Pompei R., Molicotti P., Manetti F., and Botta M. J. Med. Chem. 49 (2006) 4946-4952
24. Biava M., Porretta G.C., Poce G., Deidda D., Pompei R., Tafi A., and Manetti F. Bioorg. Med. Chem. 13 (2005) 1221-1230
25. M. Biava, M. Botta, D. Deidda, F. Manetti, R. Pompei, G.C. Porretta. WO2006092822, OC/ACT/PCT 92767.
26. Biava M., Porretta G.C., Deidda D., Pompei R., Tafi A., and Manetti F. Bioorg. Med. Chem. 11 (2003) 515-520
27. Navarrete-Vazquez G., Molina-Salinas G.M., Duarte-Fajardo Z.V., Vargas-Villarreal J., Estrada-Soto S., Gonzalez-Salazar F., Hernandez-Nunez E., and Said-Fernandez S. Bioorg. Med. Chem. 15 (2007) 5502-5508
28. Ragno R., Marshall G.R., Di Santo R., Costi R., Massa S., Pompei R., and Artico M. Bioorg. Med. Chem. 8 (2000) 1423-1432
29. Zhu Z.J., Krasnykh O., Pan D., Petukhova V., Yu G., Liu Y., Liu H., Hong S., Wang Y., Wan B., Liang W., and Franzblau S.G. Tuberculosis 88 (2008) S49-S63
30. NCCLS, The National Committee for Clinical Laboratory Standards. NCCLS document M24-A. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard vol. 23 (2003), NCCLS, Wayne, PE Number 18
31. Cerius2 Version 4.8.1 Accelrys, Inc., Scranton Road, San Diego, CA.
32. Ghose A.K., Viswanadhan V.N., and Wendoloski J.J. J. Phys. Chem. 102 (1998) 3762-3772